Dr. Janjigian is Chief of the Gastrointestinal Oncology Service at MSK, where her clinical practice and research are focused on improving treatment outcomes for people with esophageal and gastric (EG) cancers. She has led many clinical trials of novel therapies, especially immunotherapies and targeted therapies. In the area of immunotherapy, Dr. Janjigian led an early-phase trial demonstrating the promising activity of dual CTLA-4/PD-1 blockade in this disease, and is now the US coordinating PI on two ongoing global pivotal immunotherapy studies, including Morpheus-Gastric Cancer (evaluating multiple combinations with atezolizumab) and Checkmate649 (nivolumab with or without ipilimumab). She is also currently global PI of Keynote-811, a phase 3 trial of the combination of pembrolizumab with standard-of-care trastuzumab and chemotherapy in HER2-positive EG cancers. Her translational research aims to determine mechanisms of response and resistance to current and novel therapies to better match patients with beneficial treatment and inform the development of improved combinations. Dr. Janjigian has recently led a DoD-funded project employing 89Zr-trastuzumab-PET, rapid autopsies, and patient-derived xenografts to determine the extent of clonal evolution in treatment-refractory HER2+ EG cancer, and is currently leading a collaborative project evaluating the use of reductions in circulating tumor DNA as a readout for the efficacy of pembrolizumab in patients with EG cancer.